How would you manage a male patient who has a germline BRCA2 mutation with node-positive, HR-positive invasive ductal carcinoma who is unable/unwilling to receive tamoxifen or AI + goserelin?
1
How would you manage a male patient who has a germline BRCA2 mutation with node-positive, HR-positive invasive ductal carcinoma who is unable/unwilling to receive tamoxifen or AI + goserelin? | Mednet
